Skip to main content

Dermatology

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Oct 29, 2020

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article

Guselkumab, an IL-23 Inhibitor, Effective in Psoriatic Arthritis

Oct 28, 2020

The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.



This was a phase III trial that enrolled  biologic‐naïve PsA patients with active disease (≥5 swollen+≥5

Read Article
Swedish population study of psoriasis pts Rx w/ secukinumab (848) or ustekinumab (1107) showed slightly more respiratory infx & UTI (HR 1.22), w/ no difference in hospital treated severe respiratory, UTI (HR 0.96) or candidiasis (HR 1.80) https://t.co/yIRubED6VX

Dr. John Cush RheumNow ( View Tweet)

Oct 06, 2020
Meta-analysis shows smoking increases the risk of psoriasis (OR: 1.84) in the general population, but smoking the risk of PsA among psoriasis patients (OR: 0.70) but was equal to the general populatoin. https://t.co/4MkpkFQlqr

Dr. John Cush RheumNow ( View Tweet)

Oct 01, 2020
The RheumNow Podcast is up! Cardiovascular Risk in Psoriatic Disease, Higher COVID rates in young adults, Reimbursements for Rheumatologists and more.

Dr. John Cush RheumNow ( View Tweet)

Sep 27, 2020
High-risk coronary plaques (LRNC) assessed by Coronary CT scores in 209 biologic naive Psoriasis pts. LNRC correlated w/ Framingham risk & Dz activity.

Dr. John Cush RheumNow ( View Tweet)

Sep 25, 2020

Romilkimab Effective in Early Diffuse Systemic Sclerosis

Sep 24, 2020

A phase II study of patients with early diffuse systemic sclerosis (SSc) has demonstrated improvement in SSc skin outcomes by targeting T cells and fibrosis with the bispecific monoclonal antibody romilkimab (RMK).



Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4

Read Article
The EMAs Committee for Medicinal Products for Human Use (CHMP) has recommended baricitinib for approval in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy https://t.co/goEacN1C8X

Dr. John Cush RheumNow ( View Tweet)

Sep 23, 2020

Updated List of Drugs Inducing Lupus

Sep 14, 2020

Drugs inducing lupus may account for nearly 30% of all subacute cutaneous lupus erythematosus (CLE) and up to 15% of systemic lupus erythematosus (SLE) cases. Moreover there are over 100 drugs capable of inducing drug-induced lupus erythematosus. A population based report in JAMA

Read Article

Comorbidities Impact Disease Activity in Spondyloarthritis

Sep 13, 2020

An analysis of a large population-based cohort of axial spondyloarthritis (axSpA) patients shows that comorbidities are common and are associated with higher disease activity and higher levels of functional impairment.

Read Article
Study of 211 SSc pts (70% with limited SSc) & during 120 (50-216) mos F/U, 105 (50%) had 1 or more skin ulcer (SU); 66% recurrent/persistent SUs.

Dr. John Cush RheumNow ( View Tweet)

Sep 02, 2020
Successful treatment of refractory palmoplantar psoriasis in a psoriatic arthritis patient with the JAK inhibitor tofacitinib https://t.co/bdhppoUkmz

Dr. John Cush RheumNow ( View Tweet)

Aug 26, 2020

RheumNow Podcast – The Bad News That’s Fit to Print (8.21.20)

Aug 20, 2020

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow: filgotinib rejection, delays in diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX.

Read Article

New Criteria for Discoid Lupus

Aug 19, 2020

JAMA Dermatology has proposed an initial validation of classification criteria for discoid lupus erythematosus (DLE), primarily for research purposes, but with clinical applicatility.



Candidate criteria were prospectively develped in 215 DLE patients from international

Read Article
Hong Kong study Myositis-specific autoantibodies in 201 pts with idiopathic inflammatory myopathies (IIM) shows MDA-5 (14%), TIFF-1γ (14%), Jo-(12.4%). MDA5 seen w/ DM, digital ulcers, amyopathy, ILD.

Dr. John Cush RheumNow ( View Tweet)

Aug 07, 2020
Virtual Video Joint Exam Pearl #5: Its easier to see gouty Tophi and rheumatoid nodules than nail changes of PsA or subtle rashes. For Rashes and oral lesions its BEST to have the patient take multiple pix with the cell phone and send them in by EMR or Email.

Dr. John Cush RheumNow ( View Tweet)

Aug 04, 2020
Lenabasum (cannabinoid rcptr agonist) studied in Systemic Sclerosis - LEN (n=27) vs PBO (n=15).
Dr. John Cush RheumNow ( View Tweet)
Jul 29, 2020
The RheumNow Podcast is up - COVID-19 Responds to Steroids & TCZ, statin myopathy, Lung Dz in AOSD, TNFi & Liver, IL-23 in Psoriasis.

Dr. John Cush RheumNow ( View Tweet)

Jul 24, 2020
Cross-sectional survey of 3200 PsA/Pso patients. 65% had both joint & skin involvement. Latter pts had worse QoL, work impairment, higher TJC (5.2) & SJC (4.8) (vs 2.0 & 1.5); more flares (35 vs. 23%, p < 0.001).

Dr. John Cush RheumNow ( View Tweet)

Jul 24, 2020

Low Risk of COVID in Biologic Treated Rheum Patients

Jul 23, 2020

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 



Their study included 295

Read Article
Metanalysis of 7 RCTs looked at melanoma risk comparing 34 029 biologic Tx vs 135 370 non-biologic conventional systemic Tx pts, showing no signif.

Dr. John Cush RheumNow ( View Tweet)

Jul 23, 2020

Risankizumab Outduels Secukinumab in Psoriasis

Jul 20, 2020

The IMMerge trial has demonstrated the superiority of interleukin (IL)‐23 over IL-17A inhibition adults with plaque psoriasis.



This multicenter, phase 3, open‐label study enrolled 327 adult patients with chronic, moderate‐to‐severe plaque psoriasis who were randomised risankizumab (

Read Article
FDA has approved a 6th adalimumab biosimilar - called Hulio (adalimumab-fkjp) with indications of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, psoriasis.

Dr. John Cush RheumNow ( View Tweet)

Jul 13, 2020
Skin is often involved w/ ANCA+ vasculitis - 1184 AAV pt study shows skin involvement in 34% GPA; 28% MPA & 47% EGPA. Common are petechiae/purpura pruritus, urticaria, and maculopapular rash.

Dr. John Cush RheumNow ( View Tweet)

Jul 10, 2020

ICYMI: The Nine Lives of Hydroxychloroquine (Updated)

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory

Read Article
×